Can Higher Plavix Dose Offset PPI Effect Versus Effient? Medco Wants To Know
This article was originally published in The Pink Sheet Daily
Executive Summary
Medco is launching a preliminary study to find out whether doubling the usual dose of Bristol-Myers Squibb's Plavix can offset the problem of reduced effectiveness that comes with concurrent use of a proton pump inhibitor and show that Plavix can still be as effective in certain patients as its newer and more expensive competitor, Effient.
You may also be interested in...
GIFT Does Damage To Idea Of Double Dosing Of Plavix For Poor Responders
Increasing the dose of Plavix (clopidogrel) does not seem to be a sufficient strategy for treating patients who are poor metabolizers of the soon-to-be generic drug, according to a new trial of genetic testing for responders and contrary to a small study currently in labeling of the Bristol-Myers Squibb/Sanofi-Aventis drug.
GIFT Does Damage To Idea Of Double Dosing Of Plavix For Poor Responders
Increasing the dose of Plavix (clopidogrel) does not seem to be a sufficient strategy for treating patients who are poor metabolizers of the soon-to-be generic drug, according to a new trial of genetic testing for responders and contrary to a small study currently in labeling of the Bristol-Myers Squibb/Sanofi-Aventis drug.
GRAVITAS Fails To Show Clinical Value Of Platelet Function Testing For Plavix
Study results don't prove clinical benefit for point-of-care testing, but trial may not have been sufficiently powered to show a difference.